FDA Approves drug combination for Colorectal Patients

FDA Approves drug combination for Colorectal Patients

Ziv-

08/06/2012

Ziv-Aflibercept

On August 3, 2012, the U. S. Food and Drug Administration approved ziv-aflibercept injection (Zaltrap, Sanofi U.S., Inc.) for use in combination with 5-fluorouracil, leucovorin, irinotecan (FOLFIRI) for the treatment of patients with metastatic colorectal cancer (mCRC) that is resistant to or has progressed following an oxaliplatin‑containing regimen. Ziv-aflibercept (previously known as aflibercept) is a recombinant fusion protein consisting of vascular endothelial growth factor (VEGF)-binding portions from the extracellular domains of human VEGF receptors 1 and 2 that are fused to the Fc portion of the human IgG1 immunoglobulin.

This approval is based on the results of a randomized, double-blind, placebo-controlled, global, multicenter trial enrolling patients with mCRC that progressed during or within 6 months of receiving oxaliplatin-based combination chemotherapy, with or without prior bevacizumab.

The Phase 3 trial accrued 1226 patients who were randomly allocated (1:1) to receive FOLFIRI (irinotecan 180 mg/m2 IV infusion over 90 minutes, leucovorin 400 mg/m² IV infusion over 2 hours, followed by 5-FU 400 mg/m² IV bolus, followed by 5-FU 2400 mg/m² continuous IV infusion over 46-hours) with either ziv-aflibercept (N=612) or placebo (N=614). Ziv-aflibercept was administered at a dose of 4 mg/kg IV infusion over 1 hour prior to FOLFIRI. The treatment cycles on both arms were repeated every 2 weeks. Patients were treated until disease progression or unacceptable toxicity. The primary efficacy endpoint was overall survival (OS). Treatment assignment was stratified by the ECOG performance status and prior exposure to bevacizumab.

Median age of randomized patients was 61 years, 59% were men, and 98% had an ECOG performance status of 0 or 1. All patients had received prior oxaliplatin treatment. A statistically significant improvement in OS was observed in patients receiving FOLFIRI plus ziv-aflibercept compared to those receiving FOLFIRI plus placebo [HR 0.82 (95% CI: 0.71, 0.94), p=0.0032, stratified log-rank test]. The median OS was 13.5 and 12.06 months for patients on the ziv-aflibercept and placebo arms, respectively. Median progression-free survival in the ziv-aflibercept arm was 6.9 compared to 4.7 months in the placebo arm [HR 0.76 (95% CI: 0.66, 0.87), p=0.00007].

The most common adverse reactions, (all grades), occurring in ≥ 20% of patients in the ziv-aflibercept plus FOLFIRI arm (with > 2% difference between arms) were leukopenia, diarrhea, neutropenia, proteinuria, increased AST and ALT, stomatitis, fatigue, thrombocytopenia, hypertension, decreased weight, decreased appetite, epistaxis, abdominal pain, dysphonia, increased serum creatinine, and headache. The most common grade 3-4 adverse reactions (≥ 5%) reported at a higher incidence in the ziv-aflibercept plus FOLFIRI arm (> 2% difference between arms) were neutropenia, diarrhea, hypertension, leukopenia, stomatitis, fatigue, proteinuria, and asthenia.

Severe and sometimes fatal hemorrhages, including gastrointestinal hemorrhages, have been reported in patients receiving ziv-aflibercept. Grade 3-4 hemorrhagic events occurred in 2.9% of patients receiving FOLFIRI plus ziv-aflibercept compared with 1.7% of those receiving FOLFIRI plus placebo. In addition to hemorrhage, the ziv-aflibercept label contains a Boxed Warning for the serious adverse reactions gastrointestinal perforation and compromised wound healing.

Arterial thromboembolic events were observed in 1.7% and 2.6% of patients in the placebo and ziv-aflibercept containing arms, respectively. Venous thromboembolic events were also observed more frequently with ziv-aflibercept: 9% patients in the ziv-aflibercept-containing arm compared to 7% in the placebo-containing arm. Fistula formation and reversible posterior leukoencephalopathy syndrome have also been reported in patients who received ziv-aflibercept.

The recommended ziv-aflibercept dose and schedule is 4 mg/kg administered as a 60-minute IV infusion every 2 weeks in combination with the FOLFIRI regimen.

Full prescribing information, including Boxed Warning, clinical trial information, safety, dosing, and use in specific populations are available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/125418s000lbl.pdf1

Healthcare professionals should report all serious adverse events suspected to be associated with the use of any medicine and device to FDA’s MedWatch Reporting System by completing a form online at http://www.fda.gov/medwatch/report.htm, by faxing (1-800-FDA-0178) or mailing the postage-paid address form provided online, or by telephone (1-800-FDA-1088).

Are you at Risk For Colorectal Cancer?

  • 2nd leading cause of cancer deaths for men and women combined
  • Colonoscopies not only discover cancer, but can also stop cancer
  • 50% of Americans still do not get colonoscopy reimbursement
  • Colon cancer research is still vastly under-funded

Events in Your Neighborhood

November 1

Scope It Out 5K Run/Walk Salt Lake City

Salt Lake City, UT
The 1st Annual Scope It Out 5K Run/Walk Salt Lake City Read More »

November 1

3rd Annual Scope It Out 5K Run/Walk Detroit

Detroit, MI
The 3rd Annual Scope It Out 5K Run/Walk in Detroit Read More »

December 4

Fighting a Smarter War on Colorectal Cancer

Washington, DC
Join Chris4Life and Colon Cancer Alliance in a joint partnership for  Fighting a ... Read More »

Subscribe Follow